Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Mcl-1 inhibitors(Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC29H24N6O3 |
InChIKeySDVVSJQTYKFAFR-UHFFFAOYSA-N |
CAS Registry906718-66-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | CN | TYK Medicines, Inc.Startup | 22 Jul 2023 |
Triple Negative Breast Cancer | Preclinical | US | 22 Jul 2023 |